| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13127* | 2021 |
| AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity CM Chresta, BR Davies, I Hickson, T Harding, S Cosulich, SE Critchlow, ... Cancer research 70 (1), 288-298, 2010 | 914 | 2010 |
| mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling VS Rodrik-Outmezguine, S Chandarlapaty, NC Pagano, PI Poulikakos, ... Cancer discovery 1 (3), 248-259, 2011 | 515 | 2011 |
| Controlling ligand substitution reactions of organometallic complexes: Tuning cancer cell cytotoxicity F Wang, A Habtemariam, EPL van der Geer, R Fernández, M Melchart, ... Proceedings of the National Academy of Sciences 102 (51), 18269-18274, 2005 | 335 | 2005 |
| Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells P Casado, JC Rodriguez-Prados, SC Cosulich, S Guichard, ... Science signaling 6 (268), rs6-rs6, 2013 | 329 | 2013 |
| Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein … KM Foote, K Blades, A Cronin, S Fillery, SS Guichard, L Hassall, I Hickson, ... Journal of medicinal chemistry 56 (5), 2125-2138, 2013 | 244 | 2013 |
| Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent KM Foote, JWM Nissink, T McGuire, P Turner, S Guichard, JWT Yates, ... Journal of medicinal chemistry 61 (22), 9889-9907, 2018 | 231 | 2018 |
| Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines S Arnould, I Hennebelle, P Canal, R Bugat, S Guichard European journal of cancer 39 (1), 112-119, 2003 | 224 | 2003 |
| The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia L Willems, N Chapuis, A Puissant, TT Maciel, AS Green, N Jacque, ... Leukemia 26 (6), 1195-1202, 2012 | 182 | 2012 |
| Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors EM Sommer, H Dry, D Cross, S Guichard, BR Davies, DR Alessi Biochemical Journal 452 (3), 499-508, 2013 | 181 | 2013 |
| CPT-11 converting carboxylesterase and topoisomerase I activities in tumour and normal colon and liver tissues S Guichard, C Terret, I Hennebelle, I Lochon, P Chevreau, E Fretigny, ... British journal of cancer 80 (3), 364-370, 1999 | 174 | 1999 |
| Aspirin activates the NF-κB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer LA Stark, K Reid, OJ Sansom, FV Din, S Guichard, I Mayer, DI Jodrell, ... Carcinogenesis 28 (5), 968-976, 2007 | 164 | 2007 |
| AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules SM Guichard, J Curwen, T Bihani, CM D'Cruz, JWT Yates, M Grondine, ... Molecular cancer therapeutics 14 (11), 2508-2518, 2015 | 130 | 2015 |
| Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line S Guichard, I Hennebelle, R Bugat, P Canal Biochemical pharmacology 55 (5), 667-676, 1998 | 127 | 1998 |
| Practical treatment guide for dose individualisation in cancer chemotherapy P Canal, E Chatelut, S Guichard Drugs 56 (6), 1019-1038, 1998 | 121 | 1998 |
| Structure−Activity Relationships of Monomeric C2-Aryl Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Antitumor Agents D Antonow, M Kaliszczak, GD Kang, M Coffils, AC Tiberghien, N Cooper, ... Journal of medicinal chemistry 53 (7), 2927-2941, 2010 | 118 | 2010 |
| Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells P Sini, D James, C Chresta, S Guichard Autophagy 6 (4), 553-554, 2010 | 112 | 2010 |
| Sequence‐dependent activity of the irinotecan‐5FU combination in human colon‐cancer model HT‐29 in vitro and in vivo S Guichard, D Cussac, I Hennebelle, R Bugat, P Canal International journal of cancer 73 (5), 729-734, 1997 | 105 | 1997 |
| Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055) SV Holt, A Logie, BR Davies, D Alferez, S Runswick, S Fenton, ... Cancer research 72 (7), 1804-1813, 2012 | 100 | 2012 |
| Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium (II … RL Hayward, QC Schornagel, R Tente, JS Macpherson, RE Aird, ... Cancer chemotherapy and pharmacology 55, 577-583, 2005 | 100 | 2005 |
